The purpose of this study is to compare the effect of arzoxifene to raloxifene on the bone mineral density (bone strength)...
Date First Received: September 29, 2006
Last Updated: August 20, 2008
Verified by: Eli Lilly and Company, August 2008
Clinical Trial Phase: Phase 3 | Start Date: October 2006
Overall Status: Completed
Estimated Enrollment: 320
Brief Summary
Official Title: “The Comparison of the Efficacy and Safety of Arzoxifene Versus Raloxifene in Postmenopausal Women With Osteoporosis”
Condition Keyword(s):
Intervention(s):
The purpose of this study is to compare the effect of arzoxifene to raloxifene on the bone mineral density (bone strength).
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study
Study Primary Completion Date: June 2008
Intervention(s) in this Clinical Trial
- Drug: Arzoxifene
- 20 mg, oral, tablet, once a day for 52 weeks
- Drug: Raloxifene
- 60 mg, oral, tablet, once a day for 52 weeks
Arms, Groups and Cohorts in this Clinical Trial
- Experimental: 1
- Active Comparator: 2
Outcome Measures for this Clinical Trial
Primary Measures
- Percent change in Lumbar Spine BMD
- Time Frame: baseline to 12 months
Safety Issue?: No
- Time Frame: baseline to 12 months
Secondary Measures
- Secondary BMD measures of total hip and femoral neck
- Time Frame: at 6 and 12 months
Safety Issue?: No
- Time Frame: at 6 and 12 months
- Biochemical markers of bone metabolism assessed
- Time Frame: baseline, 3, 6, and 12 months
Safety Issue?: No
- Time Frame: baseline, 3, 6, and 12 months
- Assessment of coagulation parameters
- Time Frame: baseline, 3, 6, and 12 months
Safety Issue?: No
- Time Frame: baseline, 3, 6, and 12 months
- Breast Density by mammogram
- Time Frame: screening and 12 months
Safety Issue?: No
- Time Frame: screening and 12 months
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Must have osteoporosis
- Must be between 50 and 75 years old and be able to walk
- Have at least two of your back bones that can be x-rayed
- Have not had a period in at least two years
- Be willing to have blood tests
Exclusion Criteria:
- Have a bone disease other than osteoporosis
- History of estrogen dependent cancer
- History of stroke or certain heart problems
- Possibly have an allergy to raloxifene or arzoxifene
- Have certain abnormal lab values
- History of seizure disorder
- Have unexplained vaginal bleeding or an abnormal pap smear
Gender Eligibility for this Clinical Trial: Female
Minimum Age for this Clinical Trial: 50 Years
Maximum Age for this Clinical Trial: 75 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: Eli Lilly and Company
Overall Clinical Trial Officials and Contacts
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST) Study Director Eli Lilly and Company
Additional Information
Information obtained from ClinicalTrials.gov on October 07, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00383422
Study ID Number: 8580
ClinicalTrials.gov Identifier: NCT00383422
Health Authority: United States: Food and Drug Administration
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.